dc.contributor.author | Lechosa Muñiz, Carolina | |
dc.contributor.author | Paz Zulueta, María | |
dc.contributor.author | Mendez-Legaza, Jose Manuel | |
dc.contributor.author | Irure Ventura, Juan | |
dc.contributor.author | Cuesta González, Rocío | |
dc.contributor.author | Calvo Montes, Jorge | |
dc.contributor.author | López Hoyos, Marcos | |
dc.contributor.author | Llorca Díaz, Francisco Javier | |
dc.contributor.author | Cabero Pérez, María Jesús | |
dc.contributor.other | Universidad de Cantabria | es_ES |
dc.date.accessioned | 2022-02-01T17:23:15Z | |
dc.date.available | 2022-02-01T17:23:15Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 1661-7827 | |
dc.identifier.issn | 1660-4601 | |
dc.identifier.uri | http://hdl.handle.net/10902/23824 | |
dc.description.abstract | Breastfeeding mothers were excluded from the clinical trials conducted for vaccines against SARS-CoV-2. Since the start of the vaccination, some doubts have arisen regarding its compatibility with breastfeeding. The aim of this study was to analyse the presence of anti-SARS-CoV-2 antibodies in breast milk and serum (IgG and IgA) of vaccinated breastfeeding women. The main variables of the observational study were: adverse related events after vaccination and determination of the presence of IgG and IgA isotypes antibodies in serum and in breast milk of vaccinated women against the SARS-CoV-2 antigens. Results: 110 breastfeeding mothers were included; 70 women (63.6%) were vaccinated with two doses of BNT162b2, 20 women (18.2%) with two doses of mRNA-1273, and 20 women (18.2%) with a single dose of ChAdOx1-S. Regarding adverse reactions and vaccine safety, 38 women had no adverse reactions; 20 (18.2%) had general malaise or adenopathies; 10 (9.1%) had a headache; and 7 (6.4%) had fever. When analysing IgG antibodies, significantly higher levels of antibodies were found in serum and breast milk from mothers vaccinated with BNT162b2 or mRNA-1273 vs. ChAdOx1-S (p < 0.001 and p = 0.001, respectively). Analysing IgA antibodies, significant differences were found when comparing mean values in serum from mothers vaccinated with BNT162b2 or mRNA-1273 vs. ChAdOx1-S (0.12, 0.16, and 0.02, respectively; p < 0.001) and breast milk of mothers vaccinated when comparing BNT16b2 vs. ChAdOx1-S. All vaccinated breastfeeding mothers had serum anti-S1 IgG antibodies in response to vaccination against SARS-CoV-2, regardless of the commercial vaccine administered. Conclusions: the anti-SARS-CoV-2 vaccines were well tolerated by the mothers and the breastfed infant. In addition, breastfeeding mothers offer their infants IgA and IgG isotype antibodies directed against SARS-CoV-2 protein S in breast milk. | es_ES |
dc.format.extent | 20 p. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.source | Int J Environ Res Public Health
. 2021 Aug 21;18(16):8831 | es_ES |
dc.subject.other | Antibodies | es_ES |
dc.subject.other | Breastfeeding | es_ES |
dc.subject.other | Breast Milk | es_ES |
dc.subject.other | COVID-19 Vaccine | es_ES |
dc.subject.other | Maternal Immunity | es_ES |
dc.subject.other | Neonatal Immunity | es_ES |
dc.title | Induction of SARS-CoV-2-specific IgG and IgA in serum and milk with different SARS-CoV-2 vaccines in breastfeeding women: a cross-sectional study in northern Spain | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.accessRights | openAccess | es_ES |
dc.identifier.DOI | 10.3390/ijerph18168831 | |
dc.type.version | publishedVersion | es_ES |